BOOK
PET/MRI: Clinical Applications, An Issue of PET Clinics, E-Book
Drew A. Torigian | Andreas Kjær | Abass Alavi | Habib Zaidi
(2016)
Additional Information
Book Details
Abstract
This issue of PET Clinics focuses on PET/MRI: Clinical Applications, and is edited by Drs. Drew Torigian and Andreas Kjaer. Articles will include: PET/MRI in Prostate Cancer; PET/MRI in Vascular Disease; PET/MRI in Lymphoma; PET/MRI in Head and Neck Cancer; PET/MRI in Brain Disease; PET/MR in Cancers of GI Tract; PET/MRI in Gynecologic Cancer; Clinical PET/MRI Systems and Patient Workflow; PET/MRI in Heart Disease; PET/MR in Breast Cancer and Lung Cancer; PET/MRI in Musculoskeletal Disorders; PET/MRI in Pediatric Oncology; Clinical PET/MRI: Future Perspectives; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| PET/MRI: Clinical Applications\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface: PET/MR Imaging: Clinical Applications\r | v | ||
| 18F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma\r | v | ||
| 18F-Fluorodeoxyglucose PET/MR Imaging in Head and Neck Cancer\r | v | ||
| Clinical PET-MR Imaging in Breast Cancer and Lung Cancer\r | v | ||
| PET/MR Imaging in Cancers of the Gastrointestinal Tract\r | v | ||
| The Emerging Role of PET/MR Imaging in Gynecologic Cancers\r | vi | ||
| Clinical PET/MR Imaging in Dementia and Neuro-Oncology\r | vi | ||
| PET/MR Imaging in Musculoskeletal Disorders\r | vi | ||
| PET/MR Imaging in Heart Disease\r | vii | ||
| PET/MR Imaging in Vascular Disease: Atherosclerosis and Inflammation\r | vii | ||
| Clinical PET/MR Imaging in Oncology: Future Perspectives\r | vii | ||
| PET CLINICS\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| January 2017 | viii | ||
| April 2017 | viii | ||
| July 2017 | viii | ||
| RECENT ISSUES | viii | ||
| July 2016 | viii | ||
| April 2016 | viii | ||
| January 2016 | viii | ||
| CME Accreditation Page | ix | ||
| PROGRAM OBJECTIVE | ix | ||
| TARGET AUDIENCE | ix | ||
| LEARNING OBJECTIVES | ix | ||
| ACCREDITATION | ix | ||
| DISCLOSURE OF CONFLICTS OF INTEREST | ix | ||
| UNAPPROVED/OFF-LABEL USE DISCLOSURE | ix | ||
| TO ENROLL | ix | ||
| METHOD OF PARTICIPATION | ix | ||
| CME INQUIRIES/SPECIAL NEEDS | ix | ||
| Preface:\rPET/MR Imaging: Clinical Applications | xi | ||
| 18F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma | 363 | ||
| Key points | 363 | ||
| INTRODUCTION | 363 | ||
| ROLE OF IMAGING | 363 | ||
| COMPUTED TOMOGRAPHY | 364 | ||
| PET/COMPUTED TOMOGRAPHY | 364 | ||
| MR IMAGING | 365 | ||
| RATIONALE OF PET/MR IMAGING IN LYMPHOMA | 365 | ||
| PET/MR IMAGING TECHNIQUE | 365 | ||
| IMAGE QUALITY AND RADIOTRACER UPTAKE QUANTIFICATION | 366 | ||
| IMAGING FINDINGS | 366 | ||
| DIFFERENTIAL DIAGNOSIS IN PET/MR IMAGING OF LYMPHOMA | 367 | ||
| PITFALLS IN PET/MR IMAGING IN LYMPHOMA | 368 | ||
| Muscle Uptake | 368 | ||
| Brown Fat | 368 | ||
| Metal Artifacts | 368 | ||
| INITIAL STAGING | 369 | ||
| TREATMENT RESPONSE ASSESSMENT | 369 | ||
| RECURRENT DISEASE | 369 | ||
| RADIOTRACERS OTHER THAN 18F-FLUORODEOXYGLUCOSE | 371 | ||
| SUMMARY | 371 | ||
| REFERENCES | 371 | ||
| 18F-Fluorodeoxyglucose PET/MR Imaging in Head and Neck Cancer | 375 | ||
| Key points | 375 | ||
| INTRODUCTION | 375 | ||
| ROLE OF IMAGING AND STAGING CLASSIFICATIONS | 376 | ||
| IMAGING METHODS | 376 | ||
| COMPUTED TOMOGRAPHY | 376 | ||
| MR IMAGING | 376 | ||
| ULTRASONOGRAPHY | 376 | ||
| PET/COMPUTED TOMOGRAPHY | 376 | ||
| PET/MR IMAGING | 377 | ||
| Introduction and Rationale of PET/MR Imaging | 377 | ||
| PET/MR Imaging Technique | 377 | ||
| Image Quality and Uptake Quantification in 18F-fluorodeoxyglucose PET/MR Imaging | 378 | ||
| Imaging Findings | 378 | ||
| Pitfalls in PET/MR imaging | 380 | ||
| MUSCLE ACTIVATION | 380 | ||
| METAL ARTIFACTS | 380 | ||
| HYPOGLOSSAL NERVE PALSY | 381 | ||
| BROWN FAT | 381 | ||
| 18F-FLUORODEOXYGLUCOSE PET/MR IMAGING OF THE HEAD AND NECK COMPARED WITH OTHER IMAGING METHODS | 382 | ||
| INITIAL STAGING | 382 | ||
| FOLLOW-UP | 383 | ||
| DISTANT METASTASES, SYNCHRONOUS TUMORS, AND CARCINOMA OF UNKNOWN PRIMARY | 384 | ||
| ALTERNATIVE RADIOTRACERS | 384 | ||
| SUMMARY | 384 | ||
| REFERENCES | 385 | ||
| Clinical PET-MR Imaging in Breast Cancer and Lung Cancer | 387 | ||
| Key points | 387 | ||
| INTRODUCTION | 387 | ||
| PET-COMPUTED TOMOGRAPHY IN BREAST CANCER | 388 | ||
| MR IMAGING IN BREAST CANCER | 389 | ||
| PET-MR IMAGING IN BREAST CANCER | 390 | ||
| STANDARDIZED UPTAKE VALUE: PET-MR IMAGING VERSUS PET- COMPUTED TOMOGRAPHY IN BREAST CANCER | 390 | ||
| PET-MR IMAGING LESION DETECTION IN BREAST CANCER | 391 | ||
| TUMOR STAGING IN BREAST CANCER | 392 | ||
| ADDITIONAL PET-MR IMAGING APPLICATIONS IN BREAST CANCER: MULTIPARAMETRIC DATASETS | 392 | ||
| PET-COMPUTED TOMOGRAPHY IN LUNG CANCER | 392 | ||
| MR IMAGING IN LUNG CANCER | 394 | ||
| PET-MR IMAGING IN LUNG CANCER | 395 | ||
| STANDARDIZED UPTAKE VALUE: PET-MR IMAGING VERSUS PET- COMPUTED TOMOGRAPHY IN LUNG CANCER | 395 | ||
| PET-MR IMAGING LESION DETECTION IN LUNG CANCER | 395 | ||
| ADDITIONAL PET-MR IMAGING APPLICATIONS IN LUNG CANCER: MULTIPARAMETRIC DATASETS | 397 | ||
| SUMMARY | 397 | ||
| REFERENCES | 398 | ||
| PET/MR Imaging in Cancers of the Gastrointestinal Tract | 403 | ||
| Key points | 403 | ||
| INTRODUCTION | 403 | ||
| TECHNICAL BACKGROUND | 404 | ||
| PET/MR Imaging Systems | 404 | ||
| PET/MR IMAGING PROTOCOL | 404 | ||
| Whole-Body PET/MR Imaging Protocol | 404 | ||
| Region-Specific Dedicated MR Imaging Protocols | 404 | ||
| Workflow | 404 | ||
| CLINICAL APPLICATIONS | 405 | ||
| LIVER | 405 | ||
| Hepatocellular Carcinoma | 405 | ||
| Liver Metastases | 408 | ||
| Cholangiocarcinoma | 409 | ||
| Gallbladder Cancer | 411 | ||
| Pancreatic Carcinoma | 413 | ||
| Colorectal Cancer | 416 | ||
| SUMMARY | 418 | ||
| REFERENCES | 419 | ||
| The Emerging Role of PET/MR Imaging in Gynecologic Cancers | 425 | ||
| Key points | 425 | ||
| INTRODUCTION | 425 | ||
| PET/MR IMAGING TECHNICAL BACKGROUND | 426 | ||
| PET/MR IMAGING PROTOCOL AND WORK-FLOW DESIGN | 426 | ||
| GYNECOLOGIC CANCERS | 427 | ||
| THE POTENTIAL ADDED VALUE OF ADVANCED MR IMAGING TECHNIQUES IN GYNECOLOGIC CANCERS | 427 | ||
| THE ROLE OF PET/MR IMAGING IN GYNECOLOGIC CANCERS | 429 | ||
| Uterine Cervical Cancer | 429 | ||
| Staging | 429 | ||
| Prognosis/prediction | 432 | ||
| Endometrial Cancer | 433 | ||
| Ovarian Cancer | 435 | ||
| SUMMARY | 437 | ||
| REFERENCES | 438 | ||
| Clinical PET/MR Imaging in Dementia and Neuro-Oncology | 441 | ||
| Key points | 441 | ||
| INTRODUCTION | 441 | ||
| PET/MR IMAGING IN DEMENTIA | 442 | ||
| Brain Imaging in Dementia | 442 | ||
| PET Radiotracers in Dementia | 443 | ||
| Clinical Work Flow and Clinical Use | 443 | ||
| Future Developments in Dementia | 444 | ||
| PET/MR IMAGING IN NEURO-ONCOLOGY | 445 | ||
| MR Imaging for Brain Tumors | 445 | ||
| PET Radiotracers for Neuro-Oncology | 445 | ||
| Clinical Workflow | 446 | ||
| Clinical Use | 446 | ||
| Future Applications and Developments in Neuro-Oncology | 449 | ||
| Limitations | 450 | ||
| REFERENCES | 450 | ||
| PET/MR Imaging in Musculoskeletal Disorders | 453 | ||
| Key points | 453 | ||
| INTRODUCTION | 453 | ||
| PET/MR IMAGING IN MUSCULOSKELETAL MALIGNANCIES | 453 | ||
| Primary Malignant Bone and Soft Tissue Tumors | 453 | ||
| Benefits of PET/MR Imaging in Adult Sarcoma | 454 | ||
| Benefits of PET/MR Imaging in Pediatric Sarcoma | 456 | ||
| Combined PET/MR Protocols for Imaging of Sarcoma | 456 | ||
| Metastatic Disease of the Musculoskeletal System | 457 | ||
| PET/MR IMAGING IN INFLAMMATORY AND INFECTIOUS MUSCULOSKELETAL DISORDERS | 460 | ||
| SUMMARY, CHALLENGES, AND FUTURE DIRECTIONS | 461 | ||
| ACKNOWLEDGMENTS | 461 | ||
| REFERENCES | 461 | ||
| PET/MR Imaging in Heart Disease | 465 | ||
| Key points | 465 | ||
| INTRODUCTION | 465 | ||
| TECHNICAL REMARKS REGARDING PET/MR IMAGING IN CARDIOLOGY | 465 | ||
| General Remarks | 465 | ||
| Generation of Attenuation Correction Maps from MR Images | 466 | ||
| Frequent Issues | 467 | ||
| MR imaging–related components | 467 | ||
| Contrast media and foreign bodies | 467 | ||
| Workflow in Cardiac Imaging | 468 | ||
| CLINICAL APPLICATIONS | 470 | ||
| Myocardial Perfusion Imaging | 470 | ||
| Myocardial Viability Imaging | 470 | ||
| “Classic” viability imaging | 470 | ||
| Postinfarction viability imaging | 471 | ||
| Imaging of Inflammatory Processes in the Myocardium | 472 | ||
| Myocarditis | 473 | ||
| Sarcoidosis | 473 | ||
| Imaging postinfarction inflammation with PET/MR imaging | 473 | ||
| SUMMARY | 474 | ||
| REFERENCES | 475 | ||
| PET/MR Imaging in Vascular Disease | 479 | ||
| Key points | 479 | ||
| INTRODUCTION | 479 | ||
| MR IMAGING FOR PLAQUE CHARACTERIZATION | 480 | ||
| PET FOR MOLECULAR IMAGING OF PLAQUE DEVELOPMENT AND VULNERABILITY | 480 | ||
| 18F-fluorodeoxyglucose-PET for Atherosclerosis and Plaque Imaging | 480 | ||
| Non-fluorodeoxyglucose (FDG)-PET for Atherosclerosis and Plaque Imaging | 482 | ||
| 64Cu-DOTATATE and 68Ga-DOTATATE | 482 | ||
| 18F-fluorothymidine | 483 | ||
| 18F-NaF | 484 | ||
| Other PET tracers | 484 | ||
| POTENTIAL ADVANTAGES AND CURRENT STATUS OF HYBRID PET/MR IMAGING IN ATHEROSCLEROSIS | 484 | ||
| An Intriguing Concept and a Perfect Match | 484 | ||
| Hybrid PET/MR Imaging for Vascular Imaging of Atherosclerosis in Humans | 486 | ||
| SUMMARY | 486 | ||
| ACKNOWLEDGMENTS | 486 | ||
| REFERENCES | 486 | ||
| Clinical PET/MR Imaging in Oncology | 489 | ||
| Key points | 489 | ||
| INTRODUCTION | 489 | ||
| PET/MR IMAGING AS A REPLACEMENT FOR PET/CT IN ROUTINE ASSESSMENT IN ONCOLOGIC CLINICAL PRACTICE | 490 | ||
| WHEN PET/MR IMAGING PROVIDES COMPLEMENTARY INFORMATION | 490 | ||
| MULTIPARAMETRIC PET/MR IMAGING AND RADIOMICS | 490 | ||
| THE POTENTIAL ROLE OF HYPERPET | 491 | ||
| SUMMARY | 492 | ||
| REFERENCES | 492 |